FDA delays action date for Raptor's cystinosis drug Procysbi

12/30/2012 | American City Business Journals

The FDA postponed from Jan. 30 to April 30 its expected decision on Raptor Pharmaceutical's cystinosis drug Procysbi, a delayed-release version of cysteamine. The agency did not ask for more studies. The FDA is expected to approve Procysbi, but it has yet to decide on orphan-drug exclusivity, an analyst said.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX